{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:28:00Z","timestamp":1787772480267,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"\n Background:<\/jats:title>\n Topical antifungals especially azole group of drugs are effective agents in the treatment of dermatophytoses producing 100% clinical and mycological cure. Each of them vary having specific characteristics to tackle several clinical challenges like high relapse rate, recurrences and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Aims and Objectives:<\/jats:title>\n \n To compare the efficacy and safety of Eberconazole and Sertaconazole in\n tinea<\/jats:italic>\n infection.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n This was a randomized, observer-blinded, parallel-group study conducted at a dermatology out-patient department (OPD) of tertiary care teaching hospital in Puducherry. 85 patients with\n tinea corporis<\/jats:italic>\n and\n tinea cruris<\/jats:italic>\n infections who visited the dermatology OPD were enrolled in this study. The treatment phase involved two groups receiving either Sertaconazole 2% cream or Eberconazole 1% applied topically twice daily for 4 weeks. At the end of treatment phase, there was a 'follow-up phase' at the end of 4 weeks, where the patients were assessed clinically and mycologically. The data were analyzed using descriptive statistics using MS Excel version 2019 and SPSS version 15 for Windows.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The primary efficacy variables namely change in pruritus, erythema, induration, scaling and mycological cure significantly improved in both the groups, as compared to baseline (\n P<\/jats:italic>\n < 0.001), in the treatment phase and follow-up phase. Intergroup comparison with respect to pruritus and scaling showed significant difference (\n P<\/jats:italic>\n < 0.001), suggestive of better reduction of pruritus and scaling scores at 4 weeks with Sertaconazole when compared to Eberconazole.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Sertaconazole was better than Eberconazole in relieving signs and symptoms of dermatophytoses, especially pruritus, thereby improving patients' quality of life.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijd.ijd_893_20","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:21:23Z","timestamp":1716985283000},"page":"573","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Eberconazole vs Sertaconazole in Localised Tinea Infection"],"prefix":"10.4103","volume":"66","author":[{"given":"Mirunalini","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Srikanth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Aravinda","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Munusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20240829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/idoj.IDOJ_281_17","article-title":"Newer topical treatments in skin and nail dermatophyte infections","volume":"9","author":"Sahni","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"R2-31-20240829","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1439-0507.2008.01606.x","article-title":"Epidemiological trends in skin mycoses worldwide","volume":"51","author":"Havlickova","year":"2008","journal-title":"Mycoses"},{"key":"R3-31-20240829","first-page":"111","article-title":"Recent trends of dermatophytosis in Northeast India (Assam) and interpretation with published studies","volume":"4","author":"Naglot","year":"2015","journal-title":"Int J CurrMicrobiol App Sci"},{"key":"R4-31-20240829","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0019-5154.105284","article-title":"Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study","volume":"58","author":"Jerajani","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R5-31-20240829","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1365-2133.2012.10815.x","article-title":"Efficacy and safety of topical antifungals in the treatment of dermatomycosis: A systematic review","volume":"166","author":"Rotta","year":"2012","journal-title":"Br J Dermatol"},{"key":"R6-31-20240829","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00003495-200969030-00009","article-title":"Sertaconazole: A review of its use in the management of superficial mycoses in dermatology and gynaecology","volume":"69","author":"Croxtall","year":"2009","journal-title":"Drugs"},{"key":"R7-31-20240829","first-page":"338","article-title":"Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration","volume":"55","author":"Susilo","year":"2005","journal-title":"Arzneimittelforschung"},{"key":"R8-31-20240829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/0378-6323.93651","article-title":"Eberconazole--pharmacological and clinical review","volume":"78","author":"Moodahadu-Bangera","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R9-31-20240829","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-4632.2006.02841.x","article-title":"Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: Multicenter, randomized, double-blind, comparative trial with miconazole 2% cream","volume":"45","author":"Montero","year":"2006","journal-title":"Int J Dermatol"},{"key":"R10-31-20240829","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4103\/2229-5178.131079","article-title":"Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris","volume":"5","author":"Choudhary","year":"2014","journal-title":"Indian Dermatol Online J"},{"key":"R11-31-20240829","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4103\/ijd.IJD_126_17","article-title":"A comparative study of efficacy and safety of eberconazole versus terbinafine in patients of tinea versicolor","volume":"63","author":"Sharma","year":"2018","journal-title":"Indian J Dermatol"},{"key":"R13-31-20240829","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/ijd.IJD_206_17","article-title":"The great Indian epidemic of superficial dermatophytosis: An appraisal","volume":"62","author":"Verma","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R14-31-20240829","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4103\/0019-5154.119958","article-title":"Efficacy and safety of terbinafine hydrochloride 1% cream vs. sertaconazole nitrate 2% cream in tinea corporis and tinea cruris: A comparative therapeutic trial","volume":"58","author":"Choudhary","year":"2013","journal-title":"Indian J Dermatol"},{"key":"R15-31-20240829","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0253-7613.194850","article-title":"Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study","volume":"48","author":"Chatterjee","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"R16-31-20240829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12895-018-0073-1","article-title":"Expert consensus on the management of dermatophytosis in India (ECTODERM India)","volume":"18","author":"Rajagopalan","year":"2018","journal-title":"BMC Dermatology"},{"key":"R17-31-20240829","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0190-9622(96)80135-6","article-title":"Guidelines of care for superficial mycotic infections of the skin: Tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. Guidelines\/Outcomes Committee. American Academy of Dermatology","volume":"34","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R18-31-20240829","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/bjd.13358","article-title":"British Association of Dermatologists' guidelines for the management of onychomycosis 2014","volume":"171","author":"Ameen","year":"2014","journal-title":"Br J Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_893_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:48:11Z","timestamp":1787770091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_893_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_893_20","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}